| Details |
| Disease Name | Glioma |
| Nocoding RNA Name | CASC2 |
| Expression Pattern | down-regulated |
| Species | Homo sapiens |
| Detection Methods | qRT-PCR,Western Blot,Luciferase Reporter Assay etc. |
| Target | N/A |
| Tissue | surgically resected glioma samples |
| Treatment | Temozolomide (TMZ) |
| PubMed ID | 28121023 |
| Year | 2017 |
| Detail Description | CASC2 expression was down-regulated in glioma tissues and cell lines, and was related to a clinicopathologic features and shorter survival time. Exogenous CACS2 alone was sufficient to inhibit glioma cells’ proliferation and amplified TMZ-induced repression of cell proliferation. CACS2 overexpression could sensitize TMZ-resistant glioma cells to TMZ. Moreover, CASC2 could inhibit the miR-181a expression by direct targeting in TMZ resistant glioma cells. CASC2 up-regulated PTEN protein and down-regulated p-AKT protein through regulating miR-181a, and the effect of CASC2 on PTEN and p-AKT could be partially restored by miR-181a. With TMZ-resistant glioma tissues, miR-181a was up-regulated while PTEN was down regulated. |
NSDNA: The Nervous System Disease NcRNAome Atlas
Contact wanglh211@163.com for inquiries and feedback
© All right reserved 2016